Literature DB >> 3723187

Prognostic value of axillary lymphoscintigraphy in breast carcinoma patients.

R G McLean, G N Ege.   

Abstract

Axillary lymphoscintigraphy (AxLS) with bilateral interdigital injection of [99mTc]antimony sulfide colloid carried out concurrently with internal mammary lymphoscintigraphy in 488 patients with breast carcinoma was evaluated. Patterns of radiocolloid distribution within the ipsilateral axilla and supraclavicular fossa were compared with similar features on the contralateral side to determine whether image characteristics are significantly disrupted by prior surgery, reflect the presence of metastases, and can predict treatment failure. Interpretive criteria for AxLS were refined after correlation of the identified image components with clinical parameters including axillary surgery, lymph node histology and relapse within a follow-up period of 2 years from the study. Results indicate that AxLS is at least as accurate as clinical assessment and provides data predictive of relapse to complement axillary lymph node status although the technique cannot presently replace lymph node sampling for patient staging.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3723187

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  4 in total

Review 1.  Axillary staging of breast cancer and the sentinel node.

Authors:  G Cserni
Journal:  J Clin Pathol       Date:  2000-10       Impact factor: 3.411

2.  The prospects for imaging lymph nodes in breast cancer.

Authors:  S M Allan
Journal:  Eur J Nucl Med       Date:  1992

Review 3.  Diagnosis of axillary lymph node metastases in patients with breast cancer.

Authors:  M Noguchi; N Katev; I Miyazaki
Journal:  Breast Cancer Res Treat       Date:  1996       Impact factor: 4.872

4.  Primary tumour characteristics and axillary lymph node status in breast cancer.

Authors:  C Yiangou; S Shousha; H D Sinnett
Journal:  Br J Cancer       Date:  1999-08       Impact factor: 7.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.